SUPPLEMENT

Q2 2021 — Earnings infographic

Q2 2021PDF · 1 pages833 KB
Alex Gorsky
Chairman and
Chief Executive Officer
Johnson & Johnson
“Our second-quarter results showcase Johnson & Johnson’s
diversified portfolio, driven by strong sales and earnings
growth across our Medical Device, Consumer Health and
Pharmaceutical businesses. I’m so proud of our 136,000
colleagues who remain focused on delivering our medicines
and products to patients and consumers around the world,
in addition to advancing our pipeline with new product
launches and regulatory submissions. These accomplishments
exemplify our commitment to advancing transformational
innovations that improve the health of people and
communities everywhere while continuing to deliver
long-term value to all of our stakeholders.”
For full financial data and non-GAAP reconciliations, please refer to Johnson & Johnson’s earnings release issued on July 21, 2021, available at
http://www.investor.jnj.com/sales-earnings.cfm.
*Non-GAAP financial measure; non-GAAP financial measures should not be considered replacements for, and should be read together with, the most
comparable GAAP financial measures.
Non-GAAP measure; excludes the impact of translational currency.
Caution Concerning Forward-Looking Statements: This document contains “forward-looking statements” as defined in the Private Securities Litigation
Reform Act of 1995 regarding future operating and financial performance. You are cautioned not to rely on these forward-looking statements, which are
based on current expectations of future events. For important information about the risks and uncertainties that could cause actual results to vary materially
from the assumptions, expectations, and projections expressed in any forward-looking statements, review the “Note to Investors Concerning Forward-
Looking Statements” included in the Johnson & Johnson earnings release issued on July 21, 2021, as well as the most recently filed Johnson & Johnson
Reports on Forms 10-K and 10-Q. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future
events or developments.
2nd Quarter 2021 Results
2nd Quarter 2021 Sales
Adjusted Diluted Earnings Per Share*
$2.48 	48.5%
Increased 
Diluted Earnings Per Share
$2.35 	72.8%
Increased 
Worldwide
Increased 
$23.3B 	23.8%*
27.1%
Worldwide
Increased  	Excluding acquisitions/
divestitures on an
operational basis
Note: values may have been rounded
$7.0Medical Devices worldwide reported sales increased 62.7%
or 57.2% operationally1
. Primary operational drivers:
 
Worldwide Medical Devices Sales
Billion
Surgical Vision 	Knees 	Hips 	Spine 	Endocutters 	Energy
Wound Closure 	Biosurgery 	Electrophysiology	Contact Lens 	Trauma
Billion
$12.6 Worldwide Pharmaceutical SalesPharmaceutical worldwide reported sales increased 17.2%
or 13.6% operationally1
. Primary operational drivers:
Consumer Health worldwide reported sales increased 13.3%
or 9.2% operationally1
. Primary operational drivers:
$3.7 	Worldwide Consumer Health Sales
Billion

-- 1 of 1 --